Migalastat clinical trials
Also written Galafold, Lucerastat, OGT-923 and ACT-434964.
How each study uses migalastat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the migalastat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Aug 2018 · GALAFOLD · NDA 208623 (FDA, Drugs@FDA)
- European Union
- 25 May 2016 · Galafold · EMEA/H/C/004059 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2011 (5)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 4 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 5 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 4 |
| 2019 | 2 |
| 2022 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 24 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Migalastat is the comparator. A study of two new drugs counts under both.
- 1Venglustat · Sanofi
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test migalastat, phase 3 first.
- Dec 2026A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseasePhase 3 · Amicus Therapeutics
Studies
Open first, then newest update. How each study uses migalastat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 24
- A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry DiseaseRecruitingPhase 3Idorsia Pharmaceuticals Ltd.NCT07778667Written as Lucerastat
- A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsRecruitingPhase 3Amicus TherapeuticsNCT06904261Written as Migalastat HCl 20 mg
- A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseaseCompletedPhase 3Idorsia Pharmaceuticals Ltd.NCT03737214Written as Lucerastat
- A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseaseActive, not recruitingPhase 3Amicus TherapeuticsNCT04020055Written as migalastat HCl 150 mg
- Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry DiseaseCompletedPhase 3Amicus TherapeuticsNCT04049760Written as migalastat HCl 150 mg
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT02944474Written as Lucerastat
- A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT02944487Written as Lucerastat
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseaseCompletedPhase 3Idorsia Pharmaceuticals Ltd.NCT03425539Written as Lucerastat
- Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy SubjectsCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03380455Written as Lucerastat
- Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)CompletedPhase 3Amicus TherapeuticsNCT03500094Written as Migalastat HCl 150 mg
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseaseCompletedPhase 3Amicus TherapeuticsNCT02194985Written as migalastat HCl 150 mg
- A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart FunctionCompletedPhase 1Idorsia Pharmaceuticals Ltd.NCT03832452Written as Lucerastat (Treatment A)
- Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry DiseaseCompletedPhase 2Amicus TherapeuticsNCT01196871Written as Migalastat HCl
- Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseaseCompletedPhase 3Amicus TherapeuticsNCT01218659Written as migalastat hydrochloride
- A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedPhase 2Amicus TherapeuticsNCT00283959Written as migalastat HCl
- Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry DiseaseCompletedPhase 3Amicus TherapeuticsNCT00925301Written as migalastat hydrochloride
- A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedPhase 2Amicus TherapeuticsNCT00214500Written as migalastat HCl
- A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry DiseaseCompletedPhase 2Amicus TherapeuticsNCT00304512Written as migalastat HCl
- Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 StudyTerminatedPhase 2Amicus TherapeuticsNCT00526071Written as migalastat HCl
- Open-Label Phase 3 Long-Term Safety Study of MigalastatTerminatedPhase 3Amicus TherapeuticsNCT01458119Written as migalastat hydrochloride
See all 24 studies that test migalastat →
Given beside what is tested · 1 — migalastat is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with migalastat
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call migalastat · ClinicalTrials.gg INT003808
- MeSH (NLM) C090092migalastatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) C4XNY919FWMIGALASTATConfirmed FDA, NLM, Wikidata
- RxNorm 2054252Confirmed FDA, Wikidata
- Wikidata Q161613migalastatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78120MigalastatOne source FDA
- DrugBank DB05018One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C090092 | migalastat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | C4XNY919FW | MIGALASTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2054252 | — | Confirmed FDA, Wikidata |
| Wikidata | Q161613 | migalastat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78120 | Migalastat | One source FDA |
| DrugBank | DB05018 | — | One source Wikidata |
Also registered as lucerastat (UNII GVS3YDM418) and migalastat hydrochloride (UNII CLY7M0XD20 · RxNorm 2054264).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.